YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. Yun J, Hong MH, Kim SY, Park CW, Kim S, Yun MR, Kang HN, Pyo KH, Lee SS, Koh JS, Song HJ, Kim DK, Lee YS, Oh SW, Choi S, Kim HR, Cho BC. Clin Cancer Res. 2019 Jan 22. doi: 10.1158/1078-0432.CCR-18-2906. [Epub ahead of print]
The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. Kim HR, Park SM, Seo SU, Jung I, Yoon HI, Gabrilovich DI, Cho BC, Seong SY, Ha SJ, Youn JI. Am J Respir Crit Care Med. 2019 Jan 15;199(2):243-246. doi: 10.1164/rccm.201808-1502LE.
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Hong MH, Kim CG, Koh YW, Choi EC, Kim J, Yoon SO, Kim HR, Cho BC. Head Neck. 2018 Jan;40(1):55-62. doi: 10.1002/hed.24933. Epub 2017 Oct 16.
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, Cho BC. Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13. Review.
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. Yun MR, Choi HM, Kang HN, Lee Y, Joo HS, Kim DH, Kim HR, Hong MH, Yoon SO, Cho BC. Oncogene. 2018 Jan 18;37(3):377-388. doi: 10.1038/onc.2017.339. Epub 2017 Sep 25.
Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types. Rhee JK, Jung YC, Kim KR, Yoo J, Kim J, Lee YJ, Ko YH, Lee HH, Cho BC, Kim TM. Cancer Immunol Res. 2018 Jan;6(1):87-97. doi: 10.1158/2326-6066.CIR-17-0201. Epub 2017 Nov 15.
A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer. Park YM, Keum KC, Kim HR, Cho BC, Kim DH, Cho NH, Kim SH. Ann Surg Oncol. 2018 Apr;25(4):864-871. doi: 10.1245/s10434-017-6208-5. Epub 2017 Oct 30.
Can We Prevent Resistance to Osimertinib? Combination or Sequential. Kim MH, Lim SM, Lee K, Soo RA, Cho BC. J Thorac Oncol. 2018 Jul;13(7):877-879. doi: 10.1016/j.jtho.2018.05.012
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH, Lee SH, Ahn JS, Park K, Choi Y, Cho BC, Ahn MJ. J Thorac Oncol. 2018 Sep;13(9):1373-1382. doi: 10.1016/j.jtho.2018.05.026. Epub 2018 Jun 5.
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. Kang HN, Choi JW, Shim HS, Kim J, Kim DJ, Lee CY, Hong MH, Park SY, Park AY, Shin EJ, Lee SY, Pyo KH, Yun MR, Choi HM, Lee SS, Kim SY, Lee H, Paik S, Cho BC, Lee JG, Kim HR. Lung Cancer. 2018 Oct;124:168-178. doi: 10.1016/j.lungcan.2018.08.008. Epub 2018 Aug 11.
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y. J Thorac Oncol. 2019 Jan;14(1):99-106. doi: 10.1016/j.jtho.2018.09.004. Epub 2018 Sep 18.
Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. Pyo KH, Kim JH, Lee JM, Kim SE, Cho JS, Lim SM, Cho BC. Lung Cancer. 2019 Jan;127:112-121. doi: 10.1016/j.lungcan.2018.11.035. Epub 2018 Nov 27.
Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity. Ryu HJ, Kim EK, Cho BC, Yoon SO. Head Neck. 2019 Jan;41(1):198-207. doi: 10.1002/hed.25507. Epub 2018 Dec 10.
ByoungChul Cho, Grace K. Dy, Ramaswamy Govindan, Dong-Wan Kim, Nathan A. Pennelle, Gerard Zalcman, Benjamin Besse, Joo-Hang Kim, GoekbenKoca, Prabhu Rajagopalan, Simon Langer, Matthias Ocker, Hendrik Nogai, Fabrice Barlesi. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small cell lung cancer. Lung Cancer 123 (2018) 14?21.
Mi Ran Yun, Sun Min Lim, Seon-Kyu Kim, Hun Mi Choi, Kyoung Ho Pyo, SeongKeun Kim, Ji Min Lee, You Won Lee, Jae Woo Choi, Hye Ryun Kim, Min-Hee Hong, KeeokHaam, Nanhyung Huh, Jong-Hwan Kim, Yong Sung Kim, Hyo Sup Shim, Ross A Soo, Jin-Yuan Shih, James Chih-Hsin Yang, Mirang Kim, ByoungChul Cho. Enhancer remodeling and microRNA alterations associated with acquired resistance to ALK inhibitor. Cancer Res 2018 (In press).
Hong-Won Lee*, Byoungsan Choi*, Han Na Kang*, Hyunwoo Kim*, Ahrum Min, Minkwon Cha, Ji Young Ryu, Sangwoo Park, Jinyoung Sohn, Kihyuk Shin, Mi Ran Yun, JooYeun Han, Min Ju Shon, CherlhyunJeong, Junho Chung, Seung-Hyo Lee, Seock-Ah Im*, ByoungChul Cho*, Tae-Young Yoon* (*Co-coresponding). Profiling of protein?protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. Nature Biomedical Engineering 2018 (In press).
Garassino MC, Cho BC, Kim JH, Mazieres J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 Mar 12.
Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat Rev. 2018 Feb 20;65:1-10.
Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018 Jan 1;29 (suppl 1):i10-i19.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Jan 11;378(2):113-125.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeno J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Ozguro?lu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929
Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun-Gyoo Lee, Young JooMin, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi, Hyo Sup Shim, Jin-Haeng Chung, Yoon La Choi, Min Jeong Lee, Maria Kim, Joo-Hang Kim, Siraj M. Ali, Myung-Ju Ahn, and ByoungChul Cho. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non?Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol 2017 (e-pub) (Published with Editorial)
Hye Ryun Kim, Han Na Kang, Hyo Sup Shim, Jinna Kim, Jin Gu Lee, Chang Young Lee, Min Hee Hong, Sung-Moo Kim, Hwan Kim, Kyoung-Ho Pyo, Mi Ran Yun, Hye Ji Park, JooYeun Han, Hyun A Youn , Myung-Ju Ahn, Soonmyung Paik, Tae-Min Kim, and ByoungChul Cho. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol 2017 (e-pub).
Han Sang Kim, Hwan Kim, Han Na Kang, Chae-Won Park, Sung-Moo Kim, Sang Joon Shin, Soo Hee Kim, Sang Kyum Kim, Eun Kyung Kim, Sang Gyun Kim, Zhenlong Zheng, Kee Yang Chung, Joel Greenbowe, Siraj M. Ali, Minkyu Jung, Tae-Min Kim, ByoungChul Cho. Oncogenic BRAF fusions in Mucosal Melanomas Activate the MAPK Pathway and are Sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Oncogene 2017 (e-pub).